Biomerica Financials - Benzinga

Biomerica Inc

BMRANASDAQ

Trade with Public

Trade with Public

$2.32

-0.14-5.69%

À la clôture: Sep 25, 5:00 PM EST

$2.61

0.2912.5%

Après les heures: Sep 24, 8:35 AM EST

Aperçu Actualités Prévisions de résultatsDonnées financièresSentiment Actionnariat Comparer Rapport sur les stocks

Biomerica Financials

Biomerica (BMRA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Biomerica Q4 EPS $(0.38) Up From $(0.69) YoY, Sales $875.000K Up From $749.000K YoY

Biomerica (NASDAQ:BMRA) reported quarterly losses of $(0.38) per share. This is a 44.93 percent increase over losses of $(0.69) per share from the same period last year. The company reported $875.000 thousand in sales

Benzinga Newsdesk

PRO
Biomerica Q3 EPS $(0.44) Up From $(0.48) YoY, Sales $987.000K Down From $1.119M YoY

Biomerica (NASDAQ:BMRA) reported quarterly losses of $(0.44) per share. This is a 8.33 percent increase over losses of $(0.48) per share from the same period last year. The company reported $987.000 thousand in sales

Benzinga Newsdesk

PRO
Biomerica Q2 EPS $(0.45) Up From $(0.48) YoY, Sales $1.210M Down From $1.636M YoY

Benzinga Newsdesk

PRO
Biomerica Q1 Sales $1.380M Down From $1.807M YoY

Biomerica (NASDAQ:BMRA) reported $1.380 million in sales this quarter. This is a 23.63 percent decrease over sales of $1.807 million the same period last year.

Benzinga Newsdesk

PRO
Biomerica Q4 EPS $(0.69) Up From $(0.72) YoY, Sales $749.000K Down From $1.118M YoY

Benzinga Newsdesk

Nasdaq Down Over 2%; Abbott Laboratories Posts Upbeat Earnings

Avi Kapoor

© 2026 Benzinga | All Rights Reserved